Results of our subgroup analyses suggested a possible lack of significant difference of sustained AKI in younger patients (aged < 60 years) and those who had hypertension, diabetes or chronic kidney disease, which would support prioritizing the prescription of anti-VEGF to older people and those without hypertension, diabetes or chronic kidney disease. The gene discussed is VEGFA; the disease is hypertensive disorder.